Rhumbline Advisers decreased its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 15.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 61,542 shares of the biotechnology company’s stock after selling 11,001 shares during the period. Rhumbline Advisers owned about 0.10% of Sarepta Therapeutics worth $3,424,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of SRPT. 361 Capital LLC bought a new stake in Sarepta Therapeutics during the 3rd quarter worth approximately $1,914,000. Janney Montgomery Scott LLC bought a new position in Sarepta Therapeutics in the 3rd quarter valued at $474,000. Jennison Associates LLC boosted its position in Sarepta Therapeutics by 0.6% in the 4th quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock valued at $63,998,000 after buying an additional 6,357 shares during the last quarter. Hikari Power Ltd bought a new position in Sarepta Therapeutics in the 3rd quarter valued at $1,134,000. Finally, Oppenheimer & Co. Inc. boosted its position in Sarepta Therapeutics by 53.0% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 33,592 shares of the biotechnology company’s stock valued at $1,524,000 after buying an additional 11,639 shares during the last quarter. 84.98% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:SRPT opened at $71.74 on Friday. Sarepta Therapeutics Inc has a 12-month low of $28.14 and a 12-month high of $84.37. The company has a market cap of $4,805.80, a PE ratio of -43.74 and a beta of 1.29. The company has a debt-to-equity ratio of 0.54, a current ratio of 13.91 and a quick ratio of 12.96.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The firm had revenue of $57.30 million for the quarter, compared to the consensus estimate of $57.33 million. During the same quarter in the prior year, the firm earned ($0.71) EPS. The company’s revenue was up 961.1% on a year-over-year basis. sell-side analysts predict that Sarepta Therapeutics Inc will post -1.18 earnings per share for the current fiscal year.
Several research analysts have recently issued reports on the company. BidaskClub downgraded Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 29th. ValuEngine raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. JPMorgan Chase lifted their price target on Sarepta Therapeutics from $75.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, March 14th. Credit Suisse Group set a $100.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a research note on Thursday. Finally, Leerink Swann restated a “positive” rating and issued a $92.00 price objective (up previously from $79.00) on shares of Sarepta Therapeutics in a report on Tuesday, March 13th. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $78.87.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/sarepta-therapeutics-inc-srpt-position-cut-by-rhumbline-advisers.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.